Tertiary pediatric transplant centers with post-transplant monitoring up to 100 days
Key Highlights
Vascular complications post allo-HSCT are variable and associated with high mortality, complicating early detection and intervention.
CLS presents with hypotension, weight gain, and edema unresponsive to diuretics due to plasma leakage.
VOD is characterized by hepatomegaly, portal hypertension, ascites, weight gain ≥5%, and jaundice from hepatic sinusoidal endothelial injury.
Guideline-Based Recommendations
Diagnosis
Use clinical criteria for CLS, VOD/SOS, and TMA within 100 days post transplant.
Diagnose TMA based on Cho et al. criteria including hemolytic anemia, thrombocytopenia, and renal/CNS impairment.
Include clinical signs indicative of TMA even if full laboratory criteria are not met.
Management
Prophylactic defibrotide (6.25 mg/kg q6h) for high-risk patients to prevent VOD during first 3 weeks post transplant.
Use ursodeoxycholic acid (5 mg/kg q12h) for VOD prevention during first 30 days or longer.
Treat acute GVHD with prednisolone (2 mg/kg/day) for grade 2–3 manifestations.
Monitoring & Follow-up
Close monitoring of clinical signs and laboratory parameters for early detection of endothelial complications within first 100 days.
Grade adverse events using CTCAE 4.03, focusing on grades 2–4 for clinical significance.
Monitor weight gain, blood pressure, liver function, and hematologic parameters post transplant.
Risks
Treatment-related mortality remains a challenge despite improved HSCT practices.
Endothelial dysfunction contributes to refractory GVHD and vascular complications.
High cumulative chemotherapy burden and conditioning regimens influence complication risk.
Patient & Prescribing Data
Pediatric allo-HSCT recipients with hematologic malignancies and non-malignant disorders
Prophylactic defibrotide and ursodeoxycholic acid are commonly used to reduce VOD risk; GVHD prophylaxis mainly with cyclosporine; corticosteroids for GVHD treatment.
Clinical Best Practices
Early identification and grading of vascular complications using standardized criteria.
Implement prophylactic strategies for VOD in high-risk patients.
Tailor GVHD prophylaxis and treatment to minimize endothelial damage.
Retrospective data collection and monitoring up to day 100 post transplant to capture acute toxicity.
